TP53 mutation is associated with more invasive diseases and poorer outcomes [37, 38] in cancer patients, particularly those with HCC [39, 40], TP53 can affect the cell cycle pathway through p53/TGF-β signaling [41]. This evidence concerns the gene TGFB1 and hepatocellular carcinoma.